The Hill reports:
The co-director of the White House’s “Operation Warp Speed” will not be required to divest his investments in pharmaceutical companies and will not be subject to federal disclosure rules, according to a decision by a government watchdog.
Advocacy groups Public Citizen and Lower Drug Prices Now filed the complaint with the Department of Health and Human Services Office of Inspector General (OIG) because Moncef Slaoui, who leads “Operation Warp Speed,” has extensive ties to the pharmaceutical industry.
However, his position in the administration is on a contract and he is not considered a government employee. As such, he is not subject to the same federal disclosure rules that would require him to list his stock holdings.
Former #BigPharma exec Dr. Moncef Slaoui is allowed to remain a government contractor, a title that permits him to avoid regular ethics disclosures.
The swamp thickens. https://t.co/jkSZNM4GBq
— Accountable.US (@accountable_us) July 16, 2020